Beam Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Beam Therapeutics
BEAM Stock  USD 22.59  1.93  7.87%   
Beam Therapeutics financial statements provide useful quarterly and yearly information to potential Beam Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Beam Therapeutics financial statements helps investors assess Beam Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Beam Therapeutics' valuation are summarized below:
Gross Profit
-304 M
Market Capitalization
2.4 B
Enterprise Value Revenue
27.2491
Revenue
63.5 M
Earnings Share
(4.58)
There are over one hundred nineteen available fundamental signals for Beam Therapeutics, which can be analyzed over time and compared to other ratios. Self-guided Investors are advised to validate Beam Therapeutics' prevailing fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 19th of March 2025, Market Cap is likely to grow to about 3.5 B. Also, Enterprise Value is likely to grow to about 3.2 B

Beam Therapeutics Total Revenue

87.06 Million

Check Beam Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Beam Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 11.7 M, Interest Expense of 51.5 M or Selling General Administrative of 60.1 M, as well as many indicators such as Price To Sales Ratio of 30.53, Dividend Yield of 0.0106 or PTB Ratio of 2.92. Beam financial statements analysis is a perfect complement when working with Beam Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Beam Therapeutics Correlation against competitors.
To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.

Beam Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets846.6 M1.1 B438.8 M
Slightly volatile
Short and Long Term Debt Total122.9 M161.4 M58.6 M
Slightly volatile
Other Current Liabilities66.7 M55.9 M37 M
Slightly volatile
Total Current Liabilities135.9 M182.1 M73.1 M
Slightly volatile
Property Plant And Equipment Net145.9 M216.3 M75.6 M
Slightly volatile
Accounts Payable4.4 M3.9 M3.4 M
Slightly volatile
Cash311.3 M282 M161.8 M
Slightly volatile
Non Current Assets Total200.2 M225.7 M103.7 M
Slightly volatile
Non Currrent Assets Other8.9 M9.4 M21.8 M
Pretty Stable
Cash And Short Term Investments635.8 M850.7 M329.6 M
Slightly volatile
Common Stock Shares Outstanding60.5 M82.3 M36.9 M
Slightly volatile
Liabilities And Stockholders Equity846.6 M1.1 B438.8 M
Slightly volatile
Non Current Liabilities Total194.9 M188.2 M100.8 M
Slightly volatile
Other Current Assets28.8 M27.4 M7.6 M
Slightly volatile
Other Stockholder Equity1.2 B2.3 B604.9 M
Slightly volatile
Total Liabilities330.8 M370.3 M173.9 M
Slightly volatile
Total Current Assets646.4 M878.1 M335.1 M
Slightly volatile
Short Term Debt9.1 M13.5 M4.9 M
Slightly volatile
Common Stock516.3 K836 K269.1 K
Slightly volatile
Other Liabilities259.5 M247.1 M81.4 M
Slightly volatile
Other Assets14.8 M16.9 M8 M
Slightly volatile
Capital Stock794.2 K836 K160.6 M
Slightly volatile
Non Current Liabilities Other1.6 M1.6 M3.7 M
Slightly volatile
Net Working Capital632.4 M696.1 M352.4 M
Slightly volatile
Property Plant Equipment282.7 M269.3 M95.5 M
Slightly volatile
Long Term Debt3.4 M2.7 M4 M
Slightly volatile
Short Term Investments507.1 M568.8 M235.3 M
Slightly volatile
Capital Lease Obligations143.2 M161.4 M72.1 M
Slightly volatile
Deferred Long Term Liabilities2.5 M2.8 M3 M
Slightly volatile
Property Plant And Equipment Gross224.7 M288.4 M117.3 M
Slightly volatile
Short and Long Term Debt2.1 M2.6 M1.7 M
Slightly volatile
Common Stock Total Equity547.2 K615.6 K671.2 K
Slightly volatile
Capital Surpluse1.3 B1.4 B1.6 B
Slightly volatile

Beam Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization11.7 M23 M6.8 M
Slightly volatile
Selling General Administrative60.1 M111.5 M32 M
Slightly volatile
Other Operating Expenses294.1 M479.1 M155.5 M
Slightly volatile
Research Development233.9 M367.6 M123.5 M
Slightly volatile
Cost Of Revenue528.1 M503 M101.1 M
Slightly volatile
Total Operating Expenses294.1 M479.1 M155.5 M
Slightly volatile
Interest Income1.5 M2.9 M1.2 M
Slightly volatile
Reconciled Depreciation33.2 M31.6 M7.4 M
Slightly volatile
Non Operating Income Net Other17.5 M19.6 M21.4 M
Slightly volatile
Selling And Marketing Expenses16 M18 M19.6 M
Slightly volatile

Beam Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation126.7 M120.7 M31.6 M
Slightly volatile
Other Cashflows From Financing Activities7.8 M8.2 M18.3 M
Very volatile
Depreciation33.2 M31.6 M7.2 M
Slightly volatile
Capital Expenditures8.5 M8.9 M12 M
Slightly volatile
Total Cash From Financing Activities7.3 M7.7 M108.9 M
Slightly volatile
End Period Cash Flow265.4 M290.1 M138.1 M
Slightly volatile
Begin Period Cash Flow257.8 M444.6 M119.6 M
Slightly volatile
Change To Netincome18.5 M19.5 M69.9 M
Slightly volatile
Dividends Paid10.2 M11.4 M12.5 M
Slightly volatile
Cash And Cash Equivalents Changes316.6 M356.2 M388.3 M
Slightly volatile
Cash Flows Other Operating41.5 M46.7 M50.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio30.5332.138343.4 K
Slightly volatile
Dividend Yield0.01060.01190.013
Slightly volatile
Days Sales Outstanding1.7 K1.9 K2.1 K
Slightly volatile
Stock Based Compensation To Revenue0.290.3284
Slightly volatile
Capex To Depreciation0.270.283218.1773
Slightly volatile
EV To Sales28.7330.240642.8 K
Slightly volatile
Payables Turnover25624349.4675
Slightly volatile
Sales General And Administrative To Revenue1.671.7558791
Slightly volatile
Research And Ddevelopement To Revenue5.55.78672.2 K
Slightly volatile
Capex To Revenue0.130.1408477
Slightly volatile
Cash Per Share7.510.33545.2219
Slightly volatile
Days Payables Outstanding1.471.552.4 K
Slightly volatile
Net Debt To EBITDA0.280.29010.5814
Slightly volatile
Current Ratio3.254.82322.3695
Slightly volatile
Receivables Turnover0.140.160.17
Slightly volatile
Capex Per Share0.10.10870.2034
Slightly volatile
Revenue Per Share0.980.77170.5205
Slightly volatile
Interest Debt Per Share1.371.96110.8978
Slightly volatile
Debt To Assets0.210.14620.2886
Slightly volatile
Days Of Payables Outstanding1.471.552.4 K
Slightly volatile
Ebt Per Ebit1.30.90651.1154
Very volatile
Long Term Debt To Capitalization0.140.150.165
Slightly volatile
Quick Ratio3.544.82322.5654
Slightly volatile
Net Income Per E B T1.141.00011.0181
Slightly volatile
Cash Ratio2.491.54871.4142
Slightly volatile
Days Of Sales Outstanding1.7 K1.9 K2.1 K
Slightly volatile
Fixed Asset Turnover0.320.29370.1715
Slightly volatile
Debt Ratio0.210.14620.2886
Slightly volatile
Price Sales Ratio30.5332.138343.4 K
Slightly volatile
Asset Turnover0.0530.05750.0282
Slightly volatile

Beam Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.5 B2 B3.6 B
Slightly volatile
Enterprise Value3.2 B1.9 B3.5 B
Slightly volatile

Beam Fundamental Market Drivers

Cash And Short Term Investments850.7 M

Beam Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Beam Therapeutics Financial Statements

Beam Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Beam Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue108.9 M65.9 M
Cost Of Revenue503 M528.1 M
Total Revenue63.5 M87.1 M
Stock Based Compensation To Revenue 0.30  0.29 
Sales General And Administrative To Revenue 1.76  1.67 
Research And Ddevelopement To Revenue 5.79  5.50 
Capex To Revenue 0.14  0.13 
Revenue Per Share 0.77  0.98 
Ebit Per Revenue(6.54)(6.87)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Beam Therapeutics is a strong investment it is important to analyze Beam Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Beam Therapeutics' future performance. For an informed investment choice regarding Beam Stock, refer to the following important reports:
How To Invest In Beam
Details
Is Beam Stock a good investment?
Details
What is Beam Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Beam Therapeutics Correlation against competitors.
To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.58)
Revenue Per Share
0.772
Quarterly Revenue Growth
(0.91)
Return On Assets
(0.20)
Return On Equity
(0.44)
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY